Pfiz­er ex­pands gene ther­a­py ef­fort on he­mo­phil­ia, bag­ging rights to a Sang­amo drug in a $545M deal

With one gene ther­a­py for he­mo­phil­ia B well along the way in the clin­ic at Spark Ther­a­peu­tics, phar­ma gi­ant Pfiz­er $PFE is now ex­tend­ing its in­ter­est in the field with a pact with Sang­amo on a new gene ther­a­py for he­mo­phil­ia A.

The ex­clu­sive world­wide li­cens­ing deal on four pro­grams at the long­time gene ther­a­py biotech in­cludes SB-525, which is poised on the thresh­old of a clin­i­cal tri­al.

“Pfiz­er has made sig­nif­i­cant in­vest­ments in gene ther­a­py over the last few years and we are build­ing an in­dus­try-lead­ing ex­per­tise in re­com­bi­nant ade­no-as­so­ci­at­ed virus (rAAV) vec­tor de­sign and man­u­fac­tur­ing,” not­ed Pfiz­er R&D chief Mikael Dol­sten.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.